放宽试验入组标准对脑转移患者纳入癌症临床试验的影响:2012-2022年时间序列分析
该研究分析了2012年1月至2022年12月美国注册的针对晚期乳腺癌、结直肠癌、肺癌或黑色素瘤的I-III期干预性临床试验的入组标准,评估2017年ASCO/FoCR/FDA工作组建议发布后脑转移排除标准的变化。共纳入3077项试验,结果显示建议发布后脑转移“未排除”的比值比条件性排除增加68%(OR 1.68,95%CI 1.06-2.66,P=0.03),未排除比例从11.5%升至17.3%,条件性排除比例从82.3%降至75.2%(P=0.03),完全排除比例无显著差异(7.5% vs 6.2%,P=0.42)。
要点
- ASCO/FoCR/FDA建议发布后,脑转移未排除的比值比条件性排除增加68%(OR 1.68,95%CI 1.06-2.66,P=0.03)。
- 脑转移未排除的试验比例从11.5%升至17.3%,条件性排除比例从82.3%降至75.2%(P=0.03)。
- 脑转移完全排除的试验比例无显著差异(7.5% vs 6.2%,P=0.42)。
核心结论
- ASCO/FoCR/FDA工作组建议与脑转移排除标准从条件性排除向未排除转变相关,表明癌症临床试验界已开始改变试验撰写方式以更具包容性。
研究设计与样本
- 从ClinicalTrials.gov提取2012年1月至2022年12月美国针对晚期乳腺癌、结直肠癌、肺癌或黑色素瘤的I-III期干预性临床试验的入组标准。
- 共评估3077项试验,将脑转移标准分为未排除、条件性排除(即在某些情况下排除)或完全排除。
- 采用中断时间序列分析和多项逻辑回归评估ASCO/FoCR/FDA建议与脑转移标准变化的相关性。
主要发现
- 在506项试验(16.4%)中脑转移患者未被排除,在2263项试验(73.5%)中被条件性排除,在308项试验(10.0%)中被完全排除。
- 建议发布后,脑转移未排除相比条件性排除的比值比增加68%(OR 1.68,95%CI 1.06-2.66,P=0.03)。
- 脑转移未排除的试验比例从11.5%升至17.3%,条件性排除比例从82.3%降至75.2%(P=0.03)。
- 脑转移完全排除的试验比例无显著差异(7.5% vs 6.2%,P=0.42)。
关键数值与推荐
- ASCO/FoCR/FDA工作组于2017年10月建议修改常见入组标准以使试验更具包容性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In October 2017, an ASCO, Friends of Cancer Research (FoCR), and US Food and Drug Administration (ASCO/FoCR/FDA) task force recommended that common eligibility criteria be modified to make trials more inclusive. We examined whether patterns of exclusions regarding patients with brain metastases changed over time in relation to these recommendations. METHODS: Trial eligibility criteria were abstracted from ClinicalTrials.gov for phase I-III US-based interventional clinical trials for patients with advanced breast, colorectal, lung, or melanoma cancers from January 2012 to December 2022. Trials were examined to determine whether patients with brain metastases were not excluded, conditionally excluded (ie, excluded in some circumstances), or wholly excluded. An interrupted time series analysis with multinomial logistic regression was used to determine whether the ASCO/FoCR/FDA recommendations were associated with changes in brain metastases criteria. RESULTS: We evaluated N = 3,077 trials. Patients with brain metastases were not excluded in 506 trials (16.4%), conditionally excluded in 2,263 trials (73.5%), and wholly excluded in 308 trials (10.0%). In the postrecommendation period, we estimated a 68% increase in the odds of brain metastases not excluded compared with conditionally excluded (odds ratio, 1.68 [95% CI, 1.06 to 2.66], P = .03). The proportion of trials in which patients with brain metastases were not excluded increased (from 11.5% v 17.3%) and conditionally excluded decreased (from 82.3% to 75.2%, P = .03). We found no difference in the proportion of trials in which patients with brain metastases were wholly excluded (7.5% v 6.2%, P = .42). CONCLUSION: The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.
引用
- Xiao H, Vaidya R, Hershman DL, et al. Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. J Clin Oncol. 2024. PMID: 38537158. doi:10.1200/JCO.23.01777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。